Belgian consensus on metabolic problems associated with atypical antipsychotics

International Journal of Psychiatry in Clinical Practice

Volumn 9, Issue 2, 2005, Pages 130-137

  De Nayer, André ^a   De Hert, M ^b   Screen, A ^c   Van Gaal, L ^d   Peuskens, J ^b  

^a Hopital Sainte Therese   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c CHU SART TILMAN   (Belgium)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Consensus; Diabetes; Dyslipidemia; Metabolic; Second generation antipsychotics

Indexed keywords

AMISULPRIDE; ANTILIPEMIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; TETRAHYDROLIPSTATIN; ZIPRASIDONE;

BELGIUM; CONFERENCE PAPER; COUNSELING; DIABETES MELLITUS; DIET THERAPY; DYSLIPIDEMIA; HOSPITAL; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; KETOACIDOSIS; MEDICAL SPECIALIST; METABOLIC ACIDOSIS; METABOLIC DISORDER; OBESITY; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHIATRIST; RISK ASSESSMENT; SIDE EFFECT; WEIGHT GAIN; WORKSHOP;

EID: 21044446245     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500510018310     Document Type: Conference Paper

References (45)

1. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004;27:596-601.
2. 'Schizophrenia and Diabetes 2003' Expert Consensus Meeting, Dublin, 3-4 October 2003: consensus summary. Br J Psychiatry 2004;184:S112-4.
3. De Hert M, Van Eyck D, Peuskens H, Thys E, Peuskens J. Prevalence of impaired glucose tolerance in schizophrenic patients [abstract]. Annual Meeting of the American Psychiatric Society, 2004.
4. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2004;27:S5-10.
5. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva, 1999.
6. Palmer JP, Hirsch IB. What's in a name: Latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes. Diabetes Care 2003;26:536-8.
7. Tuomi T, Groop L, Zimmet P, Rowley M, Knowles W, Mackay I. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993;42:359-62.
8. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002;19:708-23.
9. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996;37:68-73.
10. Subramaniam M, Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 2003;48:345-7.
11. Dynes JB. Diabetes in schizophrenia and diabetes in non-psychotic medical patients. Dis Nerv Syst 1969;30:341-4.
12. Citrome LL, Jaffe AB. Relationship of atypical antipsychotics with development of diabetes mellitus. Ann Pharmacother 2003;37:1849-57.
13. Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002;16:77-89.
14. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002;63:920-30.
15. Clark C, Burge MR. Diabetes mellitus associated with atypical anti-psychotic medications. Diabetes Technol Ther 2003;5:669-83.
16. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br Med J 2002;325:243.
17. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-6.
18. Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002;63:1135-9.
19. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004;64:701-23.
20. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004;70:1-17.
21. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 2004;71:195-212.
22. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patient with schizophrenia. J Clin Psychiatry 2004;65:4-18.
23. Scheen A, De Hert M. Risque de diabete sucre sous antipsychotiques atyptiques. Méd Hyg 2004:1591-6.
24. Hedenmalm K, Hagg S, Stahl M, Mortimer O, Spigset O. Glucose intolerance with atypical antipsychotics. Drug Saf 2002;25:1107-16.
25. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med 2001;111:716-23.
26. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002;22:841-52.
27. Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003;23:735-44.
28. Koller EA, Weber J, Doraiswamy PM, Schneider BS. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 2004;65:857-63.
29. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65:267-72.
30. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, for the Conference Participants. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004;109:433-8.
31. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001;62(Suppl 27):15-26; discussion 40-1.
32. Henderson D. Medical Illness and Schizophrenia. In: Meyer J, Nasrallah H, editors. Washington, DC: Am Psy Publishing, 2003.
33. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-49.
34. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20.
35. Nasrallah H, Korn M. Metabolic Disorders in Schizophrenia: Relationship to Atypical Antipsychotic Treatment, posted 07/28/2004: Medscape Psychiatry and Mental Health schizophrenia expert column, 2004.
36. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-97.
37. Cohn T, Wolever T, Zipursky R, et al. Screening for diabetes and impaired glucose tolerance in patients on antipsychotic medication. J Neuropsychopharmacol 2002;5(Suppl I):168.
38. Rosack J. FDA to require diabetes warning on antipsychotics. Psychiatr News 2003;38:1-a-27.
39. Haffher SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997;20:1087-92.
40. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002;26(Suppl 1):33-50.
41. Gough S, Pelever R. Diabetes and its prevention: pragmatic solutions for people with schizophrenia. Br J Psychiatr 2004;184:S106-11.
42. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002;346:393-403.
43. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002;70:19-26.
44. Gianfrancesco F, Grogg A, Mahmoud R, Wang RH, Meletiche D. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther 2003;25:1150-71.
45. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-7.